Resumen de acción CSTL Castle Biosciences, Inc. es una empresa de diagnóstico molecular que ofrece soluciones para el diagnóstico y tratamiento de cánceres dermatológicos, esófago de Barrett, melanoma uveal y enfermedades mentales. Saber más
Recompensas Análisis de riesgos Ver todos los controles de riesgos Captura tus ideas, enlaces y narrativas de la empresa
Competidores de Castle Biosciences, Inc. Historial de precios y rendimiento
Resumen de las cotizaciones máximas, mínimas y variaciones del Castle Biosciences Precios históricos de las acciones Precio actual de la acción US$28.27 Máximo en las últimas 52 semanas US$35.84 Mínimo de 52 semanas US$16.97 Beta 0.91 Cambio en 1 mes 6.08% Variación en 3 meses -14.72% Cambio de 1 año 20.76% Variación en 3 años -34.15% Variación en 5 años -8.75% Variación desde la OPV 32.10%
Noticias y actualizaciones recientes
Castle Biosciences, Inc. Announces New York State Department of Health Approval of Its TissueCypher Barrett's Esophagus Test Jan 06
Castle Biosciences, Inc. Highlights Progress for Its Pipeline Atopic Dermatitis Gene Expression Profile Test Dec 24
Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences’ DecisionDx®-Melanoma Test, Contributing to Personalized Management of Patients with Melanoma Dec 13
Castle Biosciences (NASDAQ:CSTL) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway Dec 12
Castle Biosciences, Inc. Announces the Latest Data from Its Prospective, Multicenter Decide Study Exploring the Impact of Integrating Decisiondx-Melanoma Test Results into SLNB Decision-Making for Patients Recently Diagnosed with Melanoma Nov 07
Castle Biosciences, Inc. Increases Earnings Guidance for the Year 2024 Nov 05 Ver más actualizaciones
Castle Biosciences, Inc. Announces New York State Department of Health Approval of Its TissueCypher Barrett's Esophagus Test Jan 06
Castle Biosciences, Inc. Highlights Progress for Its Pipeline Atopic Dermatitis Gene Expression Profile Test Dec 24
Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences’ DecisionDx®-Melanoma Test, Contributing to Personalized Management of Patients with Melanoma Dec 13
Castle Biosciences (NASDAQ:CSTL) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway Dec 12
Castle Biosciences, Inc. Announces the Latest Data from Its Prospective, Multicenter Decide Study Exploring the Impact of Integrating Decisiondx-Melanoma Test Results into SLNB Decision-Making for Patients Recently Diagnosed with Melanoma Nov 07
Castle Biosciences, Inc. Increases Earnings Guidance for the Year 2024 Nov 05
Are Investors Undervaluing Castle Biosciences, Inc. (NASDAQ:CSTL) By 49%? Oct 15
Castle Biosciences, Inc. to Report Q3, 2024 Results on Nov 04, 2024 Oct 14
Castle Biosciences to Present New Data on Decisiondx-Melanoma and Decisiondx-Um At 21St International Congress of the Society for Melanoma Research Oct 09
Castle Biosciences, Inc.s’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma Sep 30
Castle Biosciences, Inc. Announces the Publication of New Study in Future Oncology Sep 05
Castle Biosciences: Inflection Into Profitability Aug 16
Upgrade: Analysts Just Made A Meaningful Increase To Their Castle Biosciences, Inc. (NASDAQ:CSTL) Forecasts Aug 11
Castle Biosciences, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates Aug 08
Castle Biosciences, Inc. Revises Financial Guidance for the Full Year 2024 Aug 06
Castle Biosciences, Inc.'s (NASDAQ:CSTL) 28% Share Price Surge Not Quite Adding Up Aug 04
Castle Biosciences, Inc. to Report Q2, 2024 Results on Aug 05, 2024 Jul 16
Is Castle Biosciences (NASDAQ:CSTL) A Risky Investment? Jul 12
Castle Biosciences, Inc. Announces that AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences’ TissueCypher Test Jun 24
Castle Biosciences, Inc. Announces That New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis Jun 01
Castle Biosciences, Inc. Announces to Present New Data Related to Its DecisionDx-Melanoma and DecisionDx-UM Tests At the 2024 American Society of Clinical Oncology May 31
Castle Biosciences, Inc. Announces New Data from A Study Further Confirming the Performance of its DecisionDx-UM Test as A Robust Independent Predictor of Metastasis-Free Survival (MFS) in Patients Diagnosed with UM May 10
Consensus estimates of losses per share improve by 28% May 10
First quarter 2024 earnings: EPS and revenues exceed analyst expectations May 04
Castle Biosciences, Inc. Revises Earnings Guidance for the Full Year of 2024 May 03
Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is On The Mark Apr 30
Founder notifies of intention to sell stock Apr 15
Castle Biosciences, Inc. to Report Q1, 2024 Results on May 02, 2024 Apr 12
Castle Biosciences, Inc., Annual General Meeting, May 23, 2024 Apr 11
Independent Chairman of the Board notifies of intention to sell stock Apr 07
Castle Biosciences, Inc. Announces Share New Data At the 20Th European Association of Dermato-Oncology Congress Apr 05
Castle Biosciences, Inc. Announces Board Changes Mar 28
Castle Biosciences, Inc. Announces the Publication of a New Multi-Center Performance Study of its DecisionDx-SCC Risk Stratification Test Mar 08
Founder notifies of intention to sell stock Mar 08
Consensus estimates of losses per share improve by 26% Mar 06
New minor risk - Shareholder dilution Mar 01
Full year 2023 earnings: EPS and revenues exceed analyst expectations Mar 01
Castle Biosciences, Inc. Provides Revenue Guidance for the Full Year 2024 Feb 29
Castle Biosciences, Inc. to Report Second Half, 2023 Results on Feb 28, 2024 Feb 08
Independent Chairman of the Board notifies of intention to sell stock Feb 08
Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects Jan 27
Castle Biosciences, Inc. Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii Jan 14
Castle Biosciences, Inc. Provides Revenue Guidance for the Year 2023 Jan 08
Forecast to breakeven in 2026 Dec 31
Founder exercised options and sold US$362k worth of stock Dec 13
Independent Chairman of the Board notifies of intention to sell stock Dec 06
Founder notifies of intention to sell stock Nov 24
Castle Biosciences, Inc. Announces Data from A Single-Site, Open-Label Study Demonstrating the Consistent Impact of Idgenetix®? on Medication Response and Remission Rates in Patients with Major Depressive Disorder Nov 10
Consensus estimates of losses per share improve by 21% Nov 09 Castle Biosciences, Inc. Announces New Data Showing the Ability of Its Pipeline Test in Development to Distinguish Between Responders and Non-Responders to an Atopic Dermatitis
New minor risk - Shareholder dilution Nov 04
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Nov 03
Castle Biosciences, Inc. Raises Earnings Guidance for the Full Year 2023 Nov 03
Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans Oct 31
Castle Biosciences, Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 20
Castle Biosciences, Inc. Announces New Study Demonstrating DecisionDx-Melanoma Outperforms a Nomogram Developed at the Memorial Sloan Kettering Cancer Center Oct 06
Castle Biosciences, Inc. Shares New Data Demonstrating Ability of TissueCypher Test Results to Inform Clinical Decision-Making in Patients with Non-Dysplastic Barrett's Esophagus Oct 05
Castle Biosciences, Inc. Announces TissueCypher Barrett’s Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barrett’s Esophagus Sep 15
Castle Biosciences, Inc. Announces Data from a Study Showing the Addition of Drug-Drug Interactions and Lifestyle Factors to Drug-Gene Interactions Sep 12
Consensus estimates of losses per share improve by 12% Aug 09
Founder notifies of intention to sell stock Aug 06
Castle Biosciences, Inc. Raises Revenue Guidance for the Full Year 2023 Aug 05
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 03
Independent Chairman of the Board notifies of intention to sell stock Jul 10
Castle Biosciences to Present New DecisionDx®-Melanoma Data at the American Head & Neck Society's 11th International Conference on Head and Neck Cancer Jul 08
Earnings Working Against Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Following 36% Dive Jun 13
Castle Biosciences, Inc. Presents New Data Demonstrating the Ability of DecisionDx-SCC to Identify Tumors Likely to Metastasize in Patients with Cutaneous Squamous Cell Carcinoma Deemed Low Risk by Traditional Staging Jun 13
Independent Director recently bought US$69k worth of stock Jun 11
Price target decreased by 11% to US$39.75 Jun 06
Castle Biosciences, Inc. to Share New Data on DecisionDx-Melanoma and DecisionDx-UM at the 2023 ASCO Annual Meeting Jun 04
Consensus EPS estimates fall by 16%, revenue upgraded May 10
Founder notifies of intention to sell stock May 08
Castle Biosciences, Inc. Reaffirms Revenue Guidance for the Full Year 2023 May 05
First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind May 05
Consensus EPS estimates fall by 11%, revenue upgraded Mar 07
Full year 2022 earnings: EPS exceeds analyst expectations Mar 01
Castle Biosciences, Inc. Publishes Data from Prospective, Multicenter Study, Called DECIDE Feb 10
Castle Biosciences, Inc. to Report Q4, 2022 Results on Feb 28, 2023 Feb 08
Founder notifies of intention to sell stock Feb 05
Castle Biosciences, Inc. Revises Revenue Guidance for the for Full-Year 2022 Jan 09
Founder exercised options and sold US$141k worth of stock Dec 14
Castle Biosciences Presents New Data Demonstrating the Clinical Utility and Value of DecisionDx®-SCC in Moderately and Poorly Differentiated Cutaneous Squamous Cell Carcinoma Tumors Nov 16
Founder notifies of intention to sell stock Nov 16
Founder notifies of intention to sell stock Nov 11
Independent Chairman of the Board notifies of intention to sell stock Nov 05
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Nov 03
Castle Biosciences, Inc. Revises Revenue Guidance for the Full Year 2022 Nov 03
Castle Biosciences, Inc. Presents New Data from Collaboration with the National Cancer Institute's (NCI) Surveillance, Epidemiology and End Results (SEER) Program Oct 28
Castle Biosciences, Inc. Announces New Data Showing That the Use of Tissuecypher® Barrett’S Esophagus Test Results Can Significantly Improve Management Decisions for Barrett’S Esophagus (Be) Patients with Low-Grade Dysplasia (Lgd)To Improve Health Outcomes Oct 26 Castle Biosciences, Inc. Announces New Data from Prospective, Multicenter DECIDE1 Study Oct 21
Castle Biosciences, Inc. to Report Q3, 2022 Results on Nov 02, 2022 Oct 20
Castle Biosciences, Inc. Announces Results from a Randomized Controlled Trial Show That TissueCypher® Barrett’s Esophagus Test Results Can Significantly Improve the Accuracy of Risk Assessments and Adherence to Guideline-Recommended Patient Management Oct 14
Castle Biosciences, Inc. to Present Data Supporting the Clinical Value of Its Suite of Skin Cancer Tests through Multiple Oral Presentations at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting Oct 11
Castle Biosciences Announces Publication of Study Demonstrating the Integration of DecisionDx(R)-Melanoma and Clinicopathologic Factors Provides Optimized, Survival Prognoses for Patients with Cutaneous Melanoma Sep 24
Castle Biosciences, Inc. Presents Clinical Use Scenarios for Its Diagnostic Gene Expression Profile Tests At Maui Derm Np+Pa Fall 2022 Conference Sep 22
Consensus revenue estimates increase by 10% Aug 15
Analysts Just Published A Bright New Outlook For Castle Biosciences, Inc.'s (NASDAQ:CSTL) Aug 14 Rentabilidad de los accionistas CSTL US Healthcare Mercado US 7D 6.9% 1.6% -0.9% 1Y 20.8% -0.4% 22.6%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: CSTL superó a la industria US Healthcare, que obtuvo un rendimiento del -0.4% el año pasado.
Rentabilidad vs. Mercado: CSTL obtuvo unos resultados inferiores a los del mercado US, que fueron del 22.6% el año pasado.
Volatilidad de los precios Is CSTL's price volatile compared to industry and market? CSTL volatility CSTL Average Weekly Movement 8.2% Healthcare Industry Average Movement 7.8% Market Average Movement 6.4% 10% most volatile stocks in US Market 18.7% 10% least volatile stocks in US Market 3.2%
Precio estable de las acciones: CSTL no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de CSTL (8%) se ha mantenido estable durante el año pasado.
Acerca de la empresa Castle Biosciences, Inc. es una empresa de diagnóstico molecular que ofrece soluciones para el diagnóstico y tratamiento de cánceres dermatológicos, esófago de Barrett, melanoma uveal y enfermedades mentales. Ofrece DecisionDx-Melanoma, una prueba de perfil de expresión génica (GEP) de estratificación del riesgo para identificar el riesgo de metástasis en pacientes diagnosticados de melanoma cutáneo invasivo; DecisionDx-SCC, una prueba GEP de estratificación del riesgo patentada para pacientes con carcinoma escamoso cutáneo; MyPath Melanoma, prueba utilizada para pacientes con lesiones melanocíticas de difícil diagnóstico; y TissueCypher, prueba ómica espacial para predecir el desarrollo futuro de displasia de alto grado y/o cáncer de esófago en pacientes con esófago de Barrett no displásico, con displasia indefinida o con displasia de bajo grado. Además, la empresa ofrece la prueba DecisionDx-UM, una prueba GEP de estratificación del riesgo patentada que predice el riesgo de metástasis en pacientes con melanoma uveal; e IDgenetix, una prueba farmacogenómica que ayuda a orientar el tratamiento farmacológico del trastorno depresivo mayor, la esquizofrenia, el trastorno bipolar, los trastornos de ansiedad, la fobia social, el trastorno obsesivo-compulsivo de la personalidad, el trastorno por estrés postraumático y el trastorno por déficit de atención con hiperactividad.
Mostrar más Resumen de fundamentos de Castle Biosciences, Inc. ¿Cómo se comparan los beneficios e ingresos de Castle Biosciences con su capitalización de mercado? Estadísticas fundamentales de CSTL Capitalización bursátil US$790.37m Beneficios(TTM ) US$6.08m Ingresos (TTM ) US$311.88m
130.3x Ratio precio-beneficio (PE)
2.5x Ratio precio-ventas (PS) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de CSTL Ingresos US$311.88m Coste de los ingresos US$56.45m Beneficio bruto US$255.43m Otros gastos US$249.36m Beneficios US$6.08m
Últimos beneficios comunicados
Sep 30, 2024
Próxima fecha de beneficios
n/a
Beneficios por acción (BPA) 0.22 Margen bruto 81.90% Margen de beneficio neto 1.95% Ratio deuda/patrimonio 2.3%
¿Cómo se ha desempeñado CSTL a largo plazo?
Ver rendimiento histórico y comparativa
Análisis de la empresa y estado de los datos financieros Datos Última actualización (huso horario UTC) Análisis de la empresa 2025/01/31 09:34 Precio de las acciones al final del día 2025/01/31 00:00 Beneficios 2024/09/30 Ingresos anuales 2023/12/31
Fuentes de datos Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC . Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
Paquete Datos Marco temporal Ejemplo Fuente EE.UU. * Finanzas de la empresa 10 años Cuenta de resultados Estado de tesorería Balance Estimaciones del consenso de analistas +3 años Previsiones financieras Objetivos de precios de los analistas Precios de mercado 30 años Precios de las acciones Dividendos, escisiones y acciones Propiedad 10 años Accionistas principales Información privilegiada Gestión 10 años Equipo directivo Consejo de Administración Principales avances 10 años
* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí .
Modelo de análisis y copo de nieve Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github , también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube .
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .
Fuentes analistas Castle Biosciences, Inc. está cubierta por 9 analistas. 8 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
Analista Institución Catherine Ramsey Schulte Baird Mark Massaro BTIG Kyle Mikson Canaccord Genuity
Mostrar 6 más analistas 
